Company intelligence / Profile preview

Caranx Medical

Nice, Provence-Alpes-Côte d'Azur, France

Ownership: Private
Employees: ~20
Development stage: Other

Overview

Caranx Medical received FDA clearance in early 2024 for its TAVIPILOT Soft, the first AI-based real-time guidance software for TAVI/TAVR procedures. Animal studies for the robotic solution have been conducted with the first human trials planned for 2025–2026. No human pivotal data yet.

Therapeutic areas: Cardiovascular
Modalities: DeviceArtificial Intelligence softwareRobotic-assisted procedure
Industry: Surgical Medical Devices

Partnerships

Partnerships with centers of excellence in France and abroad (names undisclosed)initiatives to collaborate with other cardiovascular-focused companies (CarvOlympics project mentioned)

Beyond the preview

Go deeper on Caranx Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Caranx Medical.

Explore the full profile